{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:05:45Z","timestamp":1774728345016,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40122-024-00665-8","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:02:01Z","timestamp":1728054121000},"page":"1705-1712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-2610","authenticated-orcid":false,"given":"Thanin","family":"Asawavichienjinda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nutchawan","family":"Jittapiromsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"665_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7326\/0003-4819-146-1-200701020-00007","volume":"146","author":"LH Calabrese","year":"2007","unstructured":"Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146:34\u201344.","journal-title":"Ann Intern Med"},{"key":"665_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/head.13589","volume":"59","author":"L Robbins","year":"2019","unstructured":"Robbins L. Erenumab side effects. Headache. 2019;59:1088\u20139.","journal-title":"Headache"},{"key":"665_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/03331024211037277","volume":"42","author":"TD Rozen","year":"2022","unstructured":"Rozen TD, Bhatt AA. Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention. Cephalalgia. 2022;42:250\u20136.","journal-title":"Cephalalgia"},{"key":"665_CR4","unstructured":"Asawavichienjinda T, Thanprasertsuk S, Anukoolwittaya P, eds. Chapter 5 Pharmacological intervention for migraine prevention. In: Thai clinical practice guidelines in the diagnosis and treatment of migraine. 1st ed. Bangkok: Tana\u00a0Press & Graphic Company Limited; 2022. pp. 38\u201354."},{"key":"665_CR5","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"665_CR6","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/STROKEAHA.119.024416","volume":"50","author":"TM Burton","year":"2019","unstructured":"Burton TM, Bushnell CD. Reversible cerebral vasoconstriction syndrome. Stroke. 2019;50:2253\u20138.","journal-title":"Stroke"},{"key":"665_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s10194-018-0910-y","volume":"19","author":"M Viana","year":"2018","unstructured":"Viana M, Sances G, Linde M, Nappi G, Khaliq F, Goadsby PJ, et al. Prolonged migraine aura: new insights from a prospective diary-aided study. J Headache Pain. 2018;19:77.","journal-title":"J Headache Pain"},{"key":"665_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39:1284\u201397.","journal-title":"Cephalalgia"},{"key":"665_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000369776","volume":"39","author":"V Wolff","year":"2015","unstructured":"Wolff V, Armspach JP, Lauer V, et al. Ischaemic strokes with reversible vasoconstriction and without thunderclap headache: a variant of the reversible cerebral vasoconstriction syndrome? Cerebrovasc Dis. 2015;39:31\u20138.","journal-title":"Cerebrovasc Dis"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/head.12794","volume":"56","author":"V Wolff","year":"2016","unstructured":"Wolff V, Ducros A. Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache. 2016;56:674\u201387.","journal-title":"Headache"},{"key":"665_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2169\/internalmedicine.6560-20","volume":"60","author":"T Matsubayashi","year":"2021","unstructured":"Matsubayashi T, Oniki A, Furuki M, Obayashi M. Reversible cerebral vasoconstriction syndrome without headache that was initially suspected of being primary angiitis of the central nervous system. Intern Med. 2021;60:2321\u20136.","journal-title":"Intern Med"},{"key":"665_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S1474-4422(12)70135-7","volume":"11","author":"A Ducros","year":"2012","unstructured":"Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11:906\u201317.","journal-title":"Lancet Neurol"},{"key":"665_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41983-023-00607-9","volume":"59","author":"MZ Ribas","year":"2023","unstructured":"Ribas MZ, Paticci\u00e9 GF, de Medeiros SDP, de Oliveira VA, Noleto FM, Dos Santos JCC. Reversible cerebral vasoconstriction syndrome: literature review. Egypt J Neurol Psychiatr Neurosurg. 2023;59:5.","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"665_CR14","unstructured":"Nesheiwat O, Al-Khoury L. Reversible cerebral vasoconstriction syndromes Jun 14. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024."},{"key":"665_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40674-020-00137-y","volume":"6","author":"T Shimoyama","year":"2020","unstructured":"Shimoyama T, Uchino K, Hajj-Ali RA. Reversible cerebral vasoconstriction syndrome: an update of recent research. Curr Treat Opt Rheum. 2020;6:55\u201370.","journal-title":"Curr Treat Opt Rheum"},{"key":"665_CR16","first-page":"3519","volume":"25","author":"TJ Song","year":"2021","unstructured":"Song TJ, Lee KH, Li H, et al. Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. Eur Rev Med Pharmacol Sci. 2021;25:3519\u201329.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"665_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/19418744231173832","volume":"13","author":"M Zhao","year":"2023","unstructured":"Zhao M, Kaiser E, Cucchiara B, Zuflacht J. Reversible cerebral vasoconstriction syndrome exacerbation after calcitonin gene-related peptide inhibitor administration. Neurohospitalist. 2023;13:415\u20138.","journal-title":"Neurohospitalist"},{"key":"665_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172726","volume":"864","author":"AS Grell","year":"2019","unstructured":"Grell AS, Haanes KA, Johansson SE, Edvinsson L, Sams A. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery\u2014potential role in conditions of severe vasoconstriction. Eur J Pharmacol. 2019;864: 172726.","journal-title":"Eur J Pharmacol"},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/0333102410362122","volume":"30","author":"L Edvinsson","year":"2010","unstructured":"Edvinsson L, Chan KY, Eftekhari S, et al. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010;30:1233\u201340.","journal-title":"Cephalalgia"},{"key":"665_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102419884943","volume":"40","author":"E Rubio-Beltran","year":"2020","unstructured":"Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, Edvinsson L. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020;40:357\u201366.","journal-title":"Cephalalgia"},{"key":"665_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s10194-023-01694-y","volume":"24","author":"YH Ling","year":"2023","unstructured":"Ling YH, Chi NF, Pan LH, Wang YF, Wu CH, Lirng JF, et al. Association between impaired dynamic cerebral autoregulation and BBB disruption in reversible cerebral vasoconstriction syndrome. J Headache Pain. 2023;24:170.","journal-title":"J Headache Pain"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00665-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00665-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:13:06Z","timestamp":1730977986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00665-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00665-8","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thanin Asawavichienjinda received honoraria for lectures and educational events from Novartis (Thailand) Ltd., Zuellig Pharma Ltd., DKSH (Thailand) Ltd., B.L. HUA & Co., Ltd., and Pfizer (Thailand) Ltd. and support for attending meetings and\/or travel from Novartis (Thailand) Ltd., Zuellig Pharma Ltd., DKSH (Thailand) Ltd., and B.L. HUA & Co., Ltd. Nutchawan Jittapiromsak has no disclosures at this time. Andrew Blumenfeld's disclosures are the following: Advisory Board: Allergan, Aeon, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Pfizer, Revance, Teva, Theranica, Tonix. Speaker: Allergan, Abbvie, Lilly, Lundbeck, Teva, Theranica. Consultant: Aeon, Allergan, Alder, Amgen, Axon, Biohaven, Lilly, Lundbeck, Pfizer, Novartis, Teva, Theranica, Tonix. Grant support: Aeon, Allergan, Abbvie, Amgen, Lundbeck, Revance. Contributing author: Abbvie, Aeon, Allergan, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica. Stock options:\u00a0Haven Health Inc., Aeon, Axon. Andrew Blumenfeld is an Editorial Board member of Pain and Therapy journal. Andrew Blumenfeld was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This case report was reviewed and approved by the Chulalongkorn Institutional Review Board (IRB No. 437\/67). The patient provided written informed consent to disclose this information, and consent was obtained for publication of potentially identifiable information. The data were retrieved from the patient\u2019s electronic medical record and logbook headache diary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}